DOP2021000147A - Combinacion terapeutica que comprende lamivudina - Google Patents

Combinacion terapeutica que comprende lamivudina

Info

Publication number
DOP2021000147A
DOP2021000147A DO2021000147A DO2021000147A DOP2021000147A DO P2021000147 A DOP2021000147 A DO P2021000147A DO 2021000147 A DO2021000147 A DO 2021000147A DO 2021000147 A DO2021000147 A DO 2021000147A DO P2021000147 A DOP2021000147 A DO P2021000147A
Authority
DO
Dominican Republic
Prior art keywords
lamivudine
therapeutic combination
treatment
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
DO2021000147A
Other languages
English (en)
Inventor
Richard Underwood Mark
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2021000147(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of DOP2021000147A publication Critical patent/DOP2021000147A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a una combinación que comprende un compuesto de la fórmula (I) (I) o una sal farmacéuticamente aceptable del mismo, lamivudina o una sal farmacéuticamente aceptable de la misma. Estas combinaciones son útiles en la inhibición de la réplica del VIH, la prevención y/o el tratamiento de la infección por VIH, y en el tratamiento de SIDA y/o ARC.
DO2021000147A 2010-01-27 2021-07-14 Combinacion terapeutica que comprende lamivudina DOP2021000147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
PCT/US2011/022219 WO2011094150A1 (en) 2010-01-27 2011-01-24 Antiviral therapy

Publications (1)

Publication Number Publication Date
DOP2021000147A true DOP2021000147A (es) 2022-01-16

Family

ID=44319704

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2012000205A DOP2012000205A (es) 2010-01-27 2012-07-18 Terapia antiviral
DO2021000147A DOP2021000147A (es) 2010-01-27 2021-07-14 Combinacion terapeutica que comprende lamivudina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DO2012000205A DOP2012000205A (es) 2010-01-27 2012-07-18 Terapia antiviral

Country Status (45)

Country Link
US (12) US20120295898A1 (es)
EP (6) EP3351249A1 (es)
JP (8) JP2013518107A (es)
KR (4) KR101883750B1 (es)
CN (2) CN105311033B (es)
AP (1) AP3551A (es)
AU (1) AU2011209788C1 (es)
BR (1) BR112012018670A2 (es)
CA (4) CA3003988C (es)
CL (1) CL2012002080A1 (es)
CO (1) CO6602152A2 (es)
CR (1) CR20120423A (es)
CY (4) CY1116509T1 (es)
DK (4) DK3127542T3 (es)
DO (2) DOP2012000205A (es)
EA (4) EA025176B1 (es)
EC (1) ECSP12012106A (es)
ES (3) ES2543066T3 (es)
FI (1) FI3494972T3 (es)
FR (1) FR18C1043I2 (es)
HK (3) HK1250335A1 (es)
HR (4) HRP20240168T1 (es)
HU (4) HUE037812T2 (es)
IL (5) IL221007A (es)
LT (4) LT3494972T (es)
LU (1) LUC00090I2 (es)
MA (1) MA34002B1 (es)
ME (2) ME03058B (es)
MX (4) MX367937B (es)
MY (1) MY188334A (es)
NO (2) NO2932970T3 (es)
NZ (4) NZ627824A (es)
PE (2) PE20160180A1 (es)
PH (2) PH12016500195A1 (es)
PL (3) PL2531027T3 (es)
PT (4) PT2531027E (es)
RS (4) RS65183B1 (es)
SG (3) SG10201509476RA (es)
SI (4) SI3127542T1 (es)
SM (1) SMT201500177B (es)
TN (1) TN2012000376A1 (es)
TR (1) TR201807704T4 (es)
UA (1) UA105556C2 (es)
WO (1) WO2011094150A1 (es)
ZA (1) ZA201205586B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2531027E (pt) 2010-01-27 2015-09-16 Viiv Healthcare Co Combinação terapêutica compreendendo dolutegravir, abacavir e lamivudina
US10004721B2 (en) 2012-10-23 2018-06-26 Cipla Limited Pharmaceutical antiretroviral composition
RS54873B1 (sr) 2012-12-21 2016-10-31 Gilead Sciences Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
EP2956123A1 (en) * 2013-02-18 2015-12-23 ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
EP3252058B1 (en) 2013-07-12 2021-01-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (es) 2013-07-12 2018-07-21
JP6081662B2 (ja) 2013-09-27 2017-02-15 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖインテグラーゼ阻害薬として有用な置換されたキノリジン誘導体
IN2014MU00916A (es) 2014-03-20 2015-09-25 Cipla Ltd
EP3151920A4 (en) 2014-06-04 2017-12-27 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (es) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
CN107074875B (zh) 2014-07-29 2019-03-29 斯洛文尼亚莱柯制药股份有限公司 度鲁特韦钠的新水合物
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3466490B1 (en) 2015-04-02 2020-10-21 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3334419A1 (en) * 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
EP3654980A1 (en) 2017-07-21 2020-05-27 VIIV Healthcare Company Regimens for treating hib infections and aids
US20200147092A1 (en) * 2017-07-21 2020-05-14 Viiv Healthcare Company Regimens for treating hiv infections and aids
MX2020003377A (es) * 2017-10-13 2020-09-28 Viiv Healthcare Co Formulacion de tableta farmaceutica de dos capas.
CA3128961A1 (en) 2019-03-22 2020-10-01 Hang CHU Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
US20230270677A1 (en) * 2020-01-09 2023-08-31 University Of Washington Long-acting therapeutic agent combinations and methods thereof
CR20220418A (es) 2020-02-24 2022-10-10 Gilead Sciences Inc Compuestos tetracíclicos para el tratamiento de infecciones por vih
LT4196479T (lt) 2021-01-19 2023-12-11 Gilead Sciences, Inc. Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
WO2023164293A1 (en) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Methods for viral infections

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
JP2000515852A (ja) * 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
AU3366899A (en) 1998-03-27 1999-10-18 Regents Of The University Of California, The Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
EP1255510B3 (en) 2000-01-31 2009-03-04 Cook Biotech, Inc. Stent valves
ME00558A (en) 2001-04-10 2011-12-20 Pyrazole derivatives for treating hiv
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
EP1536800B1 (en) 2002-06-27 2006-01-04 Medivir Ab Synergistic interaction of abacavir and alovudine
PL378368A1 (pl) * 2003-01-14 2006-04-03 Gilead Sciences, Inc. Kompozycje i sposoby wykorzystywane w skojarzonej terapii przeciwwirusowej
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CA2555176A1 (en) * 2004-02-11 2005-08-25 Smithkline Beecham Corporation Hiv integrase inhibitors
ES2315922T3 (es) * 2004-04-14 2009-04-01 Gilead Sciences, Inc. Analogos de fosfonato de compuestos inhibidores de la integrasa del vih.
EP3287130A1 (en) * 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
EP1713489B1 (en) 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium and processes for preparation thereof
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
EP1961757B1 (en) 2004-09-17 2010-09-01 IDENIX Pharmaceuticals, Inc. Phosphoindoles as HIV inhibitors
JP2008531716A (ja) 2005-03-04 2008-08-14 スミスクライン ビーチャム コーポレーション 化合物
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
AU2006239177B8 (en) 2005-04-28 2012-02-16 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
UA101141C2 (ru) * 2005-12-30 2013-03-11 Гилиад Сайенсиз, Инк. Способ улучшения фармакокинетики ингибиторов интегразы вич
KR20140082858A (ko) 2005-12-30 2014-07-02 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
EP1981506B3 (en) * 2006-01-20 2021-06-09 Janssen Sciences Ireland Unlimited Company Long term treatment of hiv- infection with tcm278
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
WO2008011117A2 (en) 2006-07-21 2008-01-24 Gilead Sciences, Inc. Antiviral protease inhibitors
ES2488922T3 (es) 2006-09-29 2014-09-01 Idenix Pharmaceuticals, Inc. Fosfoindoles enantiómeramente puros como inhibidores del HIV
HUE029866T2 (en) 2007-02-23 2017-03-28 Gilead Sciences Inc Modulation of pharmacokinetic parameters of therapeutic agents
US20080241289A1 (en) 2007-02-23 2008-10-02 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
CA2692460A1 (en) 2007-06-29 2009-01-08 Korea Research Institute Of Chemical Technology Hiv reverse transcriptase inhibitors
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
AR067412A1 (es) 2007-07-06 2009-10-07 Gilead Sciences Inc Moduladores de propiedades farmaceuticas de productos terapeuticos
RU2498979C2 (ru) 2007-07-12 2013-11-20 Тиботек Фармасьютикалз Кристаллическая форма 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
EP2217573A4 (en) 2007-11-01 2011-08-31 Uab Research Foundation TREATMENT AND PREVENTION OF VIRUS INFECTIONS
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
WO2009082819A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
WO2009082818A1 (en) 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
PT2231628E (pt) 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規１７βルパン誘導体
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
DK2320908T3 (en) * 2008-07-25 2014-03-10 Viiv Healthcare Co DOLUTEGRAVIR prodrugs
SG171731A1 (en) 2008-12-11 2011-07-28 Glaxosmithkline Llc Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
CA2955957A1 (en) 2008-12-11 2010-06-17 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
PT2531027E (pt) 2010-01-27 2015-09-16 Viiv Healthcare Co Combinação terapêutica compreendendo dolutegravir, abacavir e lamivudina
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
WO2011160024A2 (en) 2010-06-17 2011-12-22 Fuzians Biomedicals, Inc. Compounds useful as antiviral agents, compositions, and methods of use

Also Published As

Publication number Publication date
HK1179522A1 (en) 2013-10-04
EP4316599A2 (en) 2024-02-07
KR101964923B1 (ko) 2019-04-02
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
BR112012018670A2 (pt) 2018-02-06
SG10201707183TA (en) 2017-10-30
CO6602152A2 (es) 2013-01-18
HUE026849T2 (en) 2016-08-29
EP2531027A4 (en) 2013-07-03
US20200230147A1 (en) 2020-07-23
PH12016500195B1 (en) 2016-12-05
NZ627824A (en) 2016-02-26
ES2688925T3 (es) 2018-11-07
US20180200254A1 (en) 2018-07-19
JP2022071126A (ja) 2022-05-13
IL281959A (en) 2021-05-31
CY1120457T1 (el) 2019-07-10
EA201892277A1 (ru) 2019-03-29
PT2932970T (pt) 2018-06-08
EP4316599A3 (en) 2024-04-10
HRP20181531T1 (hr) 2018-11-16
SI3127542T1 (sl) 2018-11-30
EA032868B1 (ru) 2019-07-31
IL281959B (en) 2021-12-01
EP2932970A1 (en) 2015-10-21
EP3127542B1 (en) 2018-08-22
MY188334A (en) 2021-11-30
KR20160111536A (ko) 2016-09-26
ECSP12012106A (es) 2013-05-31
US20210401850A1 (en) 2021-12-30
IL267658A (en) 2019-08-29
JP6268386B2 (ja) 2018-01-31
HK1250335A1 (zh) 2018-12-14
NZ627827A (en) 2016-02-26
JP2016145204A (ja) 2016-08-12
PL2531027T3 (pl) 2016-01-29
HUE037812T2 (hu) 2018-09-28
EP3494972B1 (en) 2023-12-13
CA2967453A1 (en) 2011-08-04
UA105556C2 (uk) 2014-05-26
SG10201509476RA (en) 2015-12-30
ME03058B (me) 2019-01-20
US20170079982A1 (en) 2017-03-23
US20170119777A1 (en) 2017-05-04
US20150238496A1 (en) 2015-08-27
EA202190473A3 (ru) 2021-12-31
KR20180078358A (ko) 2018-07-09
EP3351249A1 (en) 2018-07-25
DK2531027T3 (en) 2015-07-20
DK2932970T3 (en) 2018-05-28
LTPA2018013I1 (lt) 2018-11-12
AP2012006445A0 (en) 2012-08-31
CA3060290A1 (en) 2011-08-04
MX356891B (es) 2018-06-19
JP2017008087A (ja) 2017-01-12
RS57728B1 (sr) 2018-12-31
CN102791129B (zh) 2015-09-30
US20160339033A1 (en) 2016-11-24
AU2011209788A1 (en) 2012-08-16
US20160199379A1 (en) 2016-07-14
TN2012000376A1 (en) 2014-01-30
PL3127542T3 (pl) 2019-03-29
MX2012008774A (es) 2012-08-17
NZ627826A (en) 2016-01-29
US10426780B2 (en) 2019-10-01
DOP2012000205A (es) 2012-10-15
LT3494972T (lt) 2024-03-12
US20170216284A1 (en) 2017-08-03
AP3551A (en) 2016-01-18
US11234985B2 (en) 2022-02-01
LT3127542T (lt) 2018-11-26
EA201690872A3 (ru) 2016-12-30
HUS1800042I1 (hu) 2018-11-28
EA037601B1 (ru) 2021-04-20
AU2011209788C1 (en) 2014-08-28
LT2932970T (lt) 2018-06-25
EP3127542A1 (en) 2017-02-08
CN102791129A (zh) 2012-11-21
US20170281636A1 (en) 2017-10-05
IL257267B (en) 2019-08-29
PT3494972T (pt) 2024-02-12
DK3127542T3 (en) 2018-11-12
EA201290583A1 (ru) 2013-04-30
HUE040554T2 (hu) 2019-03-28
PT3127542T (pt) 2018-11-26
PH12018502489A1 (en) 2020-06-15
FR18C1043I2 (fr) 2019-10-11
MA34002B1 (fr) 2013-02-01
CA2967453C (en) 2018-07-17
JP2021091705A (ja) 2021-06-17
CN105311033A (zh) 2016-02-10
IL257267A (en) 2018-03-29
IL221007A0 (en) 2012-09-24
EP2531027A1 (en) 2012-12-12
CY2018029I1 (el) 2019-07-10
EA025176B1 (ru) 2016-11-30
NO2018036I1 (no) 2018-10-15
CA3060290C (en) 2022-07-12
US20120295898A1 (en) 2012-11-22
IL245182A0 (en) 2016-06-30
ES2670811T3 (es) 2018-06-01
CA2787691C (en) 2018-07-17
KR20120128640A (ko) 2012-11-27
KR101883750B1 (ko) 2018-07-31
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
FI3494972T3 (fi) 2024-03-01
PL2932970T3 (pl) 2018-08-31
AU2011209788B2 (en) 2014-02-06
LTC2932970I2 (lt) 2022-04-25
NZ601319A (en) 2014-08-29
CY1121040T1 (el) 2019-12-11
EA202190473A2 (ru) 2021-06-30
EP3494972A1 (en) 2019-06-12
CA2787691A1 (en) 2011-08-04
KR20170078868A (ko) 2017-07-07
WO2011094150A1 (en) 2011-08-04
SI2531027T1 (sl) 2015-08-31
CY2018029I2 (el) 2019-07-10
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
ME02182B (me) 2015-10-20
CA3003988A1 (en) 2011-08-04
CN105311033B (zh) 2019-05-07
JP2019167371A (ja) 2019-10-03
HK1209629A1 (en) 2016-04-08
LUC00090I2 (es) 2019-01-08
FR18C1043I1 (es) 2018-11-30
EP2531027B1 (en) 2015-05-06
CA3003988C (en) 2020-01-07
CY1116509T1 (el) 2017-03-15
SI2932970T1 (en) 2018-07-31
JP2013518107A (ja) 2013-05-20
SI3494972T1 (sl) 2024-03-29
ES2543066T3 (es) 2015-08-14
MX367938B (es) 2019-09-12
IL245182B (en) 2018-04-30
HRP20180855T1 (hr) 2018-06-29
RS65183B1 (sr) 2024-03-29
DK3494972T3 (da) 2024-01-29
JP2023085431A (ja) 2023-06-20
US20180098992A1 (en) 2018-04-12
RS54123B1 (en) 2015-12-31
TR201807704T4 (tr) 2018-06-21
CL2012002080A1 (es) 2012-11-30
IL267658B (en) 2021-04-29
CR20120423A (es) 2012-11-22
PE20121524A1 (es) 2012-12-03
SMT201500177B (it) 2015-09-07
PH12016500195A1 (en) 2016-12-05
JP2018127473A (ja) 2018-08-16
EA201690872A2 (ru) 2016-08-31
NO2932970T3 (es) 2018-08-18
EP2932970B1 (en) 2018-03-21
KR101830715B1 (ko) 2018-04-04
MX367937B (es) 2019-09-12
HRP20150770T1 (hr) 2015-08-28
PT2531027E (pt) 2015-09-16

Similar Documents

Publication Publication Date Title
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
DOP2019000201A (es) Compuestos inhibidores del vih
CR20130043A (es) Compuestos terapéuticos
PE20151654A1 (es) Inhibidores de cdc7
PH12015501156A1 (en) Pharmaceutical compositions
CY1118774T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
MX2013008012A (es) Tratamiento para la lipodistrofia.
PA8850801A1 (es) Compuestos útiles para inhibir chk1
ECSP13012551A (es) Terapia de combinación para tratar infección por hcv.
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
DOP2014000030A (es) Procedimientos para la fabricación de medicamentos útiles para el tratamiento de infecciones virales
CO6630124A2 (es) Terapia de combinación que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinético
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
UY33939A (es) Inhibidores de la péptido desformilasa
EA019080B9 (ru) α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА
MX2022001266A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
MX2022001271A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
AR109364A1 (es) Compuestos antivirales
EA033921B9 (ru) Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа